Kazia Receives FDA Orphan Designation for GDC-0084

SYDNEY, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) ... Biopharmaceuticals, Oncology, FDA Kazia Therapeutics, GDC-0084, glioblastoma multiforme
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news